Videos

Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings

Breast cancer survivors age 66 and older are more likely to die of cardiovascular disease (CVD) than they are of the cancer itself.

An FDA advisory committee unanimously recommended Wednesday that the agency withdraw the breast cancer indication for Avastin.

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Nearly half of older women with advanced breast cancer in the United States failed to receive radiation following a mastectomy.

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Older women with estrogen receptor (ER)-negative metastatic breast cancer have a 39% lower risk of all-cause mortality if they receive chemotherapy within 6 months of their diagnosis.

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

One issue that confronts medical oncologists is the explanation of benefits from chemotherapy

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer

Breast cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Breast imaging technology has evolved in recent years, and although the mammogram remains the gold standard for screening, researchers are excited about the possibilities of molecular breast imaging

Investigators have documented a wide variation in the extent to which women with early-stage breast cancer worry about the possibility of recurrent disease

Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.

Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer

Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

As a child Joyce Ann O'Shaughnessy enjoyed science and her home chemistry set. Still, she didn't give much thought to pursuing the subject beyond the confines of her school - until she faced a tragedy.

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

3D mammogram system approved, NCCN 2011 Avastin breast cancer guidelines, and the approval of generic docetaxel.

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity